Vericel (VCEL) turned in its most convincing quarter of the year. It reported third-quarter earnings of $0.27 per share against a consensus estimate of $0.02, a 1,250.0% surprise, on revenue of $85.37 million that topped the $78.3 million consensus by 9.0%. Earnings grew 170.0% year over year and revenue rose 26.5%. Management raised full-year revenue guidance for the third straight quarter, to $344-$346 million, and lifted its adjusted EBITDA margin target for the first time this year, to roughly 28% from 27%. Revenue also exceeded the company's own $76.5-$78.5 million guide by a wide margin. The central development is that growth reaccelerated to 26% from 22% in the second quarter. That sharpens the question of how much of the upside is durable and how much came from the inherently lumpy burn franchise.
The quality of the beat holds up well, with one caveat. The earnings leverage came from operations, not accounting. Gross margin was flat at 73%, while operating expenses rose only about 9% to $50.4 million against 26% revenue growth. As a result, GAAP operating income jumped to $12.2 million from $3.5 million a year ago. Adjusted EBITDA rose 48% to $25.2 million, a 30% margin that compares with 25% a year ago, 19% in the second quarter and a 21-22% guide. The caveats sit elsewhere. Gross margin remains below the reaffirmed full-year target of about 75%. Free cash flow of $15.7 million was actually lower than last year's $19.5 million as operating cash flow softened. The balance sheet is pristine, with $235.6 million in cash and investments and no debt, and the company repurchased $8.8 million of stock in the quarter.
Beneath the headline, the mix matters. MACI revenue grew 21% to $67.4 million, its sixth consecutive quarter of 20%-plus growth. That is a modest deceleration from 23% in the second quarter, although the comparison was tougher. The leading indicators point the other way. MACI biopsy growth has accelerated every quarter this year, October was the strongest biopsy month since launch, and MACI Arthro posted record cases. On that basis, management raised its fourth-quarter MACI framework to roughly 21% growth, or about $102 million, from high teens. Burn Care was the swing factor. It surged 52% to a record $18.0 million from $12 million in each of the first two quarters. Epicel hit a record $12.7 million, commercial NexoBrid reached $2.3 million, and $3.0 million of BARDA procurement revenue was recognized.
That burn contribution is where bears have legitimate ammunition. Management's fourth-quarter burn guide of about $12 million implies a sequential step back, and catastrophic burn volumes remain unpredictable. BARDA revenue should continue, with about $3 million expected in the fourth quarter and roughly $4 million in the first quarter of 2027, but it is procurement-driven rather than organic demand. Two other risks surfaced on the call:
- Management signaled it will set initial 2027 guidance conservatively, anchored near consensus and below the current run-rate.
- A competing cartilage technology has launched in Europe and the U.K. ahead of MACI's entry, although management dismissed the threat.
On the catalyst side, the U.K. launch looks increasingly concrete. NICE accepted MACI for appraisal and the MHRA completed its facility inspection, keeping a second-half 2027 launch on track. Management also suggested it is outpacing its midterm targets of roughly $500 million in revenue and high-30s EBITDA margins by the end of the decade.
The market setup is more complicated than the surprise implies. Investor sentiment entered the report more negative, slipping to -0.29 from -0.15. That is a meaningful but not dramatic deterioration. Price action explains the mood. Shares set a 52-week high of $49.32 on the day after the July report, then slid to $37.35 by mid-September. Heading into this release they had recovered to $45.48. That level is still 7.0% below the post-July opening price, but 21.8% off the low and 17.5% above the 200-day moving average. The Earnings Whispers trend readings are mostly positive, with sequential growth and momentum improving, while the AVWAP trend remains negative. That pattern is consistent with a stock that has rebounded without reclaiming its post-July highs.
The bottom line is that Vericel delivered a genuine beat-and-raise driven by operating leverage, accelerating MACI procedure indicators and an improved margin outlook. It also leaves investors with a cleaner long-term story heading into the U.K. launch. The skeptical view rests on a burn quarter that will not repeat in the fourth quarter, gross margin still short of target, and management's stated intent to guide 2027 cautiously. With sentiment soured and shares still below their post-July peak, the fundamental case improved more than market expectations did.